1856 related articles for article (PubMed ID: 33558079)
41. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
[TBL] [Abstract][Full Text] [Related]
42. Chiral distinction between hydroxychloroquine enantiomers in binding to angiotensin-converting enzyme 2, the forward receptor of SARS-CoV-2.
Aiello F; Balzano F; Uccello Barretta G; D'Acquarica I; Mazzoccanti G; Agranat I
J Pharm Biomed Anal; 2024 Jan; 237():115770. PubMed ID: 37879140
[TBL] [Abstract][Full Text] [Related]
43. Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS-evaluation of whole blood, plasma, and serum as sample matrices.
Carlsson H; Hjorton K; Abujrais S; Rönnblom L; Åkerfeldt T; Kultima K
Arthritis Res Ther; 2020 Jun; 22(1):125. PubMed ID: 32475347
[TBL] [Abstract][Full Text] [Related]
44. Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID-19: A simulation study.
Okada JI; Yoshinaga T; Washio T; Sawada K; Sugiura S; Hisada T
Clin Transl Sci; 2021 May; 14(3):1092-1100. PubMed ID: 33404133
[TBL] [Abstract][Full Text] [Related]
45. The Efficacy of Long-Term Hydroxychloroquine Use in the Prevention of COVID-19: A Retrospective Cohort Study.
Finkelstein J; Huo X
Stud Health Technol Inform; 2023 Jun; 305():303-306. PubMed ID: 37387023
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of Hydroxychloroquine Blood Concentrations and Effects in Childhood-Onset Systemic Lupus Erythematosus.
Zahr N; Urien S; Funck-Brentano C; Vantomme H; Garcelon N; Melki I; Boistault M; Boyer O; Bader-Meunier B
Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33802811
[TBL] [Abstract][Full Text] [Related]
47. Serosurvey for Health-Care Workers Provides Supportive Evidence for the Effectiveness of Hydroxychloroquine Prophylaxis against SARS-CoV-2 Infection.
Yadav RM; Pate A; Shankarkumar A; Athalye S; Shinde S; Bargir UA; Pate M; Ganpule M; Pruthi M; Patil H; Madkaikar MR
J Epidemiol Glob Health; 2021 Sep; 11(3):283-288. PubMed ID: 34514761
[TBL] [Abstract][Full Text] [Related]
48. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?
Derwand R; Scholz M
Med Hypotheses; 2020 Sep; 142():109815. PubMed ID: 32408070
[TBL] [Abstract][Full Text] [Related]
49. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.
COVID-19 RISK and Treatments (CORIST) Collaboration
Eur J Intern Med; 2020 Dec; 82():38-47. PubMed ID: 32859477
[TBL] [Abstract][Full Text] [Related]
50. Population Pharmacokinetics of Hydroxychloroquine Sulfate in Healthcare Workers, Given for Prophylaxis Against Coronavirus Disease 2019 (COVID-19) in India.
Raj JP; Gogtay NJ; Pandey A; Kakkar AK; Shafiq N; Mekala P; Pingali U; Raju AP; Mallayasamy S; Kshirsagar NA
J Clin Pharmacol; 2022 Nov; 62(11):1403-1411. PubMed ID: 35656997
[TBL] [Abstract][Full Text] [Related]
51. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
52. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
[TBL] [Abstract][Full Text] [Related]
53. The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel.
Alsmadi MM; Jaradat MM; Obaidat RM; Alnaief M; Tayyem R; Idkaidek N
AAPS PharmSciTech; 2023 Aug; 24(6):172. PubMed ID: 37566183
[TBL] [Abstract][Full Text] [Related]
54. Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study.
Chen Z; Liu A; Cheng Y; Wang X; Xu X; Huang J; Ma Y; Gao M; Huang C
BMC Infect Dis; 2021 Aug; 21(1):805. PubMed ID: 34384388
[TBL] [Abstract][Full Text] [Related]
55. Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics.
Liu WD; Chang SY; Lan TY; Lin YC; Kao JH; Liao CH; Tsai MJ; Kuo PH; Huang YS; Wang JT; Sheng WH; Hsieh SC; Chiang BL; Chen YC; Chang SC
J Formos Med Assoc; 2021 May; 120(5):1269-1273. PubMed ID: 32888840
[TBL] [Abstract][Full Text] [Related]
56. Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study.
Moes DJAR; van Westerloo DJ; Arend SM; Swen JJ; de Vries A; Guchelaar HJ; Joosten SA; de Boer MGJ; van Gelder T; van Paassen J
Clin Pharmacokinet; 2022 Feb; 61(2):231-247. PubMed ID: 34633645
[TBL] [Abstract][Full Text] [Related]
57. Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19.
Albariqi AH; Chang RYK; Tai W; Ke WR; Chow MYT; Tang P; Kwok PCL; Chan HK
J Aerosol Med Pulm Drug Deliv; 2021 Feb; 34(1):20-31. PubMed ID: 33179983
[No Abstract] [Full Text] [Related]
58. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19).
Chen CP; Lin YC; Chen TC; Tseng TY; Wong HL; Kuo CY; Lin WP; Huang SR; Wang WY; Liao JH; Liao CS; Hung YP; Lin TH; Chang TY; Hsiao CF; Huang YW; Chung WS; Cheng CY; Cheng SH;
PLoS One; 2020; 15(12):e0242763. PubMed ID: 33264337
[TBL] [Abstract][Full Text] [Related]
59. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
[TBL] [Abstract][Full Text] [Related]
60. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis.
Carmichael SJ; Charles B; Tett SE
Ther Drug Monit; 2003 Dec; 25(6):671-81. PubMed ID: 14639053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
